Last reviewed · How we verify
Gemcitabine + Nab-paclitaxel
Gemcitabine and nab-paclitaxel work together as a chemotherapy combination to disrupt cancer cell division and microtubule stability.
Gemcitabine and nab-paclitaxel work together as a chemotherapy combination to disrupt cancer cell division and microtubule stability. Used for Metastatic pancreatic cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | Gemcitabine + Nab-paclitaxel |
|---|---|
| Also known as | abraxane, Gemcitabine + Abraxane |
| Sponsor | Verastem, Inc. |
| Drug class | Chemotherapy combination (nucleoside analog + taxane) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, disrupting replication and transcription. Nab-paclitaxel is a taxane that stabilizes microtubules and prevents their disassembly, blocking mitosis. The combination leverages complementary mechanisms to enhance cytotoxicity against rapidly dividing cancer cells.
Approved indications
- Metastatic pancreatic cancer
- Non-small cell lung cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Fatigue
- Peripheral neuropathy
- Diarrhea
- Mucositis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (PHASE1)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine + Nab-paclitaxel CI brief — competitive landscape report
- Gemcitabine + Nab-paclitaxel updates RSS · CI watch RSS
- Verastem, Inc. portfolio CI